European randomized study of prostate cancer screening : first-year results of the Finnish trial.
Approximately 20 000 men 55-67 years of age from two areas in Finland were identified from the Population Registry and randomized either to the screening arm (1/3) or the control arm (2/3) of a prostate cancer screening trial.
In the first round, the participation rate in the screening arm was 69%. Of the 5053 screened participants, 428 (8.5%) had a serum prostate-specific antigen (PSA) concentration of 4.0 ng/ml or higher, and diagnostic examinations were performed on 399 of them.
A total of 106 cancers were detected among them corresponding to a positive predictive value of 27%, which is comparable with mammography screening for breast cancer.
The prostate cancer detection rate based on a serum PSA concentration of 4.0 ng ml-1 or higher was 2.1%. Approximately nine out of ten screen-detected prostate cancers were localized (85% clinical stage T1-T2) and well or moderately differentiated (42% World Health Organization (WHO) grade I and 50% grade II), which suggests a higher proportion of curable cancers compared with cases detected by other means.
Mots-clés Pascal : Tumeur maligne, Prostate, Antigène spécifique prostate, Marqueur tumoral, Dépistage, Randomisation, Finlande, Europe, Homme, Appareil génital mâle pathologie, Appareil urinaire pathologie, Prostate pathologie
Mots-clés Pascal anglais : Malignant tumor, Prostate, Prostate specific antigen, Tumoral marker, Medical screening, Randomization, Finland, Europe, Human, Male genital diseases, Urinary system disease, Prostate disease
Notice produite par :
Inist-CNRS - Institut de l'Information Scientifique et Technique
Cote : 99-0145055
Code Inist : 002B14D02. Création : 16/11/1999.